To evaluate the anti-oxidant and anti-diabetic action of Dolichos Trilobus Linn. in Wistar albino rats

Abstract

Aim: The chief motive for doing the research is to estimate the therapeutic outcomes of aqueous extract of Dolichos trilobus to respond diabetes induced by Streptozotocin. Materials & methods: The primary focus is to calculate the therapeutic effects of Dolichos trilobus given once orally to the two test groups. Thirty Wistar Albino rats were equally circulated between five groups. Study of Dolichos trilobus aqueous extract was carried out for 21 days. During this period twelve rats were divided to form two different groups and were given a dose of“200 mg/kg/day, 400 mg/kg/day”. No mortality was seen at 400mg/kg even after constantly dosing for next 21 days, considered it safe. Control group was given distilled water on the dose of 10ml/kg/day orally. Streptozotocin was given to both the Negative group as well as Standard group on the dose of 60mg/kg/day via Intra-peritoneal route. Glibenclamide has been set to the Standard group on the dose of 10mg/kg/day orally. Aqueous extract of Dolichos trilobus (Sickle Bean) was given to the Test-1 group on the dose of 200mg/kg/day orally. Aqueous extract of Dolichos trilobus was given to the Test-2 group at a dose of 400mg/kg/day orally. Results: Streptozotocin causes hypoinsulinemia and hyperglycemia due to production of pancreatic islet β-cell destruction. The diabetes was confirmed by increased level of glucose in blood, lipid per oxidation (MDA level), reduction in GSH level, food intake, body weight and histopathological variations were seen in negative group are compared to control group. This evaluation has shown that there was no major diversity in between Standard group and Test-3 (Aqueous extract of Dolichos trilobus 200 mg/kg) group. It means Test-3 have nearly same therapeutic efficacy as standard drug. Conclusion: The conclusion of the research indicates that the aqueous extract for